Newly Diagnosed AML in an Older Adult: Fitness, Goals, and Treatment Intensity
A 74-year-old man presents with 3 weeks of fatigue and gum bleeding. CBC: WBC 42 × 10^9/L with 55% blasts, hemoglobin 7.8 g/dL, platelets 14 × 10^9/L. Bone marrow shows 70% myeloblasts; cytogenetics are normal, and molecular testing shows NPM1 mutation and FLT3-ITD (allelic ratio 0.6). He lives independently, drives, and plays golf twice weekly. Comorbidities: well-controlled hypertension, eGFR 62, ejection fraction 55%. He is cognitively intact and, when asked, says 'I want to fight this, but I don't want to spend my last months in a hospital.' His daughter, who is present, pushes for 'the strongest chemotherapy possible.'
1. How do you assess fitness for intensive induction, and what does his disease biology add to the decision?
Read the worked answer
Fitness assessment. Use a validated tool (e.g., HCT-CI, geriatric assessment, Karnofsky/ECOG). He is functionally independent, cognitively intact, has preserved organ function, and few comorbidities - this suggests he is a candidate for intensive therapy despite age 74. Age alone should not exclude intensive induction.
Biology. NPM1-mutated AML is relatively favorable, and FLT3-ITD at high allelic ratio modifies risk upward. FLT3 inhibitors (midostaurin with 7+3, or gilteritinib in relapsed/refractory) improve outcomes in FLT3-mutated disease. NPM1 mutation predicts better response to chemotherapy and is a favorable marker for measurable residual disease (MRD) monitoring.
Synthesis. His biology and fitness both support an intensive approach with a FLT3 inhibitor added, with curative intent if he tolerates induction. But his stated goal - avoiding prolonged hospitalization at end of life - must shape how aggressively you pursue transplant consolidation and how you handle early complications.
2. His daughter demands 'the strongest chemotherapy.' How do you reconcile her request with the patient's stated goals and the practical realities of intensive induction in a 74-year-old?
Read the worked answer
Acknowledge the daughter's concern - she is expressing love and fear, not obstruction. Validate it explicitly before redirecting.
Clarify decisional authority. The patient is cognitively intact and is the decision-maker. Ask him, in her presence, to confirm his goals. Use teach-back: 'What does a good outcome look like to you?'
Reframe 'strongest' as 'best-matched.' Intensive induction in a fit 74-year-old is reasonable but entails ~4–6 weeks of hospitalization, prolonged cytopenias, infection risk, and 30-day mortality in the range of 10–20% even in fit older adults. 'Strongest' is not synonymous with 'best.'
Offer a concrete plan that honors both: intensive induction with FLT3 inhibitor, with an explicit checkpoint after remission (MRD status, tolerance) to reassess consolidation and transplant candidacy. Set expectations for what 'time in hospital' looks like and what stopping rules apply.
Document the goals-of-care conversation and the shared decision. Involve palliative care early for symptom support, not only at end of life.
3. What role does measurable residual disease (MRD) play in guiding his post-remission plan?
Read the worked answer
Role of MRD. In NPM1-mutated AML, MRD can be tracked by quantitative RT-PCR for the NPM1 transcript; persistence or reappearance predicts relapse and inferior survival.
How it changes management.
- If he achieves morphologic remission and MRD is negative, he may be able to avoid the most aggressive consolidation (e.g., allogeneic transplant) if his goals favor quality of life.
- If MRD remains positive after induction/consolidation, that signals high relapse risk and argues for more aggressive consolidation or transplant evaluation, even at his age, if he remains fit.
Practical caveats. MRD assays vary; use a validated, sensitive assay and consistent lab. MRD should inform, not dictate, decisions - integrate with FLT3-ITD status, tolerance, and his stated goals. Document how MRD results were used in the plan.